A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis

被引：160

作者：

Comabella, M. ^{[1
]}

Luenemann, J. D. ^{[2
]}

Rio, J. ^{[1
]}

Sanchez, A. ^{[3
]}

Lopez, C. ^{[1
]}

Julia, E. ^{[1
]}

Fernandez, M. ^{[1
]}

Nonell, L. ^{[1
]}

Camina-Tato, M. ^{[1
]}

Deisenhammer, F. ^{[4
]}

Caballero, E. ^{[5
]}

Tortola, M. T. ^{[5
]}

Prinz, M. ^{[6
]}

Montalban, X. ^{[1
]}

Martin, R. ^{[7
]}

机构：

[1] Univ Autonoma Barcelona, Unitat Neuroimmunol Clin, CEM Cat,Hosp Univ Vall Hebron, Ctr Esclerosi Multiple Catalunya,Dept Med, Barcelona 08035, Spain

[2] Rockefeller Univ, Lab Viral Immunobiol, Christopher H Browne Ctr Immunol & Immune Dis, New York, NY 10021 USA

[3] Univ Barcelona, Fac Biol, Dept Estadist, E-08028 Barcelona, Spain

[4] Innsbruck Med Univ, Dept Clin Neurol, A-6020 Innsbruck, Austria

[5] HUVH, Microbiol Serv, Barcelona 08035, Spain

[6] Univ Freiburg, Inst Neuropathol, D-79106 Freiburg, Germany

[7] Icrea, Barcelona 08035, Spain

来源：

BRAIN | 2009年 / 132卷

关键词：

multiple sclerosis; monocytes; gene-expression signature; interferon-beta; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PERIPHERAL-BLOOD CELLS; TIME QUANTITATIVE PCR; DENDRITIC CELLS; GENE-EXPRESSION; IFN-BETA; IMMUNE-RESPONSE; VIRAL-INFECTION; DOUBLE-BLIND; T-CELLS;

D O I：

10.1093/brain/awp228

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The effect of interferon-beta in multiple sclerosis is modest and many patients do not respond to treatment. To date, no single biomarker reliably correlates with responsiveness to interferon-beta in multiple sclerosis. In the present study, genome-wide expression profiling was performed in peripheral blood mononuclear cells from 47 multiple sclerosis patients treated with interferon-beta for a minimum of 2 years and classified as responders and non-responders based on clinical criteria. A validation cohort of 30 multiple sclerosis patients was included in the study to replicate gene-expression findings. Before treatment, interferon-beta responders and non-responders were characterized by differential expression of type I interferon-induced genes with overexpression of the type interferon-induced genes in non-responders. Upon treatment the expression of these genes remained unaltered in non-responders, but was strongly upregulated in responders. Functional experiments showed a selective increase in phosphorylated STAT1 levels and interferon receptor 1 expression in monocytes of non-responders at baseline. When dissecting this type I interferon signature further, interferon-beta non-responders were characterized by increased monocyte type I interferon secretion upon innate immune stimuli via toll-like receptor 4, by increased endogenous production of type I interferon, and by an elevated activation status of myeloid dendritic cells. These findings indicate that perturbations of the type I interferon signalling pathway in monocytes are related to lack of response to interferon-beta, and type I interferon-regulated genes may be used as response markers in interferon-beta treatment.

引用

页码：3353 / 3365

页数：13

共 44 条

[11] Selective blockade of the inhibitory Fcγ receptor (Fcγ RIIB) in human dendritic cells and monocytes induces a type I interferon response program [J].

Dhodapkar, Kavita M. ;

Banerjee, Devi ;

Connolly, John ;

Kukreja, Anjli ;

Matayeva, Elyana ;

Veri, Maria Concetta ;

Ravetch, Jeffrey V. ;

Steinman, Ralph M. ;

Dhodapkar, Madhav V. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2007, 204 (06) :1359-1369

[12] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

[13] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[14] Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients [J].

Gneiss, C. ;

Tripp, P. ;

Reichartseder, F. ;

Egg, R. ;

Ehling, R. ;

Lutterotti, A. ;

Khalil, M. ;

Kuenz, B. ;

Mayringer, I. ;

Reindl, M. ;

Berger, T. ;

Deisenhammer, F. .

MULTIPLE SCLEROSIS JOURNAL, 2006, 12 (06) :731-737

[15] Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome [J].

Gottenberg, JE ;

Cagnard, N ;

Lucchesi, C ;

Letourneur, F ;

Mistou, S ;

Lazure, T ;

Jacques, S ;

Ba, N ;

Ittah, M ;

Lepajolec, C ;

Labetoulle, M ;

Ardizzone, M ;

Sibilia, J ;

Fournier, C ;

Chiocchia, G ;

Mariette, X .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (08) :2770-2775

[16] Analysis of gene, expression profiles in human systemic lupus erythematosus using oligonucleotide microarray [J].

Han, GM ;

Chen, SL ;

Shen, N ;

Ye, S ;

Bao, CD ;

Gu, YY .

GENES AND IMMUNITY, 2003, 4 (03) :177-186

[17] Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector [J].

Helbig, KJ ;

Lau, DTY ;

Semendric, L ;

Harley, HAJ ;

Beard, MR .

HEPATOLOGY, 2005, 42 (03) :702-710

[18] Experimental autoimmune encephalomyelitis repressed by microglial paralysis [J].

Heppner, FL ;

Greter, M ;

Marino, D ;

Falsig, J ;

Raivich, G ;

Hövelmeyer, N ;

Waisman, A ;

Rülicke, T ;

Prinz, M ;

Priller, J ;

Becher, B ;

Aguzzi, A .

NATURE MEDICINE, 2005, 11 (02) :146-152

[19] Exploration, normalization, and summaries of high density oligonucleotide array probe level data [J].

Irizarry, RA ;

Hobbs, B ;

Collin, F ;

Beazer-Barclay, YD ;

Antonellis, KJ ;

Scherf, U ;

Speed, TP .

BIOSTATISTICS, 2003, 4 (02) :249-264

[20] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].

Jacobs, LD ;

Cookfair, DL ;

Rudick, RA ;

Herndon, RM ;

Richert, JR ;

Salazar, AM ;

Fischer, JS ;

Goodkin, DE ;

Granger, CV ;

Simon, JH ;

Alam, JJ ;

Bartoszak, DM ;

Bourdette, DN ;

Braiman, J ;

Brownscheidle, CM ;

Coats, ME ;

Cohan, SL ;

Dougherty, DS ;

Kinkel, RP ;

Mass, MK ;

Munschauer, FE ;

Priore, RL ;

Pullicino, PM ;

Scherokman, BJ ;

WeinstockGuttman, B ;

Whitman, RH ;

Baird, WC ;

Fillmore, M ;

Bona, LM ;

ColonRuiz, ME ;

Nadine, BS ;

Donovan, A ;

Bennett, S ;

Kieffer, YM ;

Umhauer, MA ;

Miller, CE ;

Kilic, AK ;

Sargent, EL ;

Schachter, M ;

Shucard, DW ;

Weider, V ;

Catalano, BA ;

Cervi, JM ;

Czekay, C ;

Farrell, JL ;

Filippini, JS ;

Matyas, RC ;

Michienzi, KE ;

Ito, M ;

OMalley, JA .

ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294

← 1 2 3 4 5 →